Private investing through venture capital vehicles is an important driver of the US economy and the source of much innovation. The start to 2022 for the industry is mixed because while fundraising, and investing in firms, appears strong, many recent exits don’t look so good, which may clog up the back end of the cycle. About 200 financings of $100 million or more were announced in the first quarter, but deal size and valuation for late-stage companies declined, likely reflecting the complete evaporation of IPOs and a decline in M & A activity. Investors begin to worry about their exits in late-stage firms. Fundraising appeared strong, with $70B in new fund commitments announced, but much of this reflects activity that actually occurred last year, with closings just now being finalized. Fundraising is likely to slow as exits slow. (NVCA Report)
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
February 4, 2023
Coronamonomania Lives Forever, Part 190
Still doing my best to keep you up on the research relevant to the epidemic,…
Commentary
February 3, 2023
Minnesota Dems Go Full-on Crazy
Minnesota has gone full on lunatic in policy.
Commentary
February 3, 2023
(Biggest Sigh Yet) Can We Finally Acknowledge Masks Are Pointless
The most prestigious source for evidence-based medicine and a large study once more demonstrate the…